Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. for securities fraud, with a deadline for investors to seek lead plaintiff status by March 24, 2026 [1][2]. Group 1: Company Overview - Beyond Meat, headquartered in El Segundo, California, develops plant-based food products and sells meat alternatives under the "Beyond" brand in the U.S. and internationally [2]. Group 2: Financial Performance and Challenges - As market conditions deteriorated, Beyond Meat committed to achieving EBITDA-positive operations by the end of 2026, focusing on expense reduction, margin improvement, and operational efficiency [3]. - On October 24, 2025, Beyond Meat announced an expected material impairment charge, leading to a stock price drop of over 23% in one trading day [4]. - Subsequent disclosures in November 2025 regarding delayed SEC filings and $77.4 million in impairment charges resulted in further stock declines of approximately 16%, 9%, and 9%, causing significant investor losses [4].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. on behalf of investors who acquired its securities during the specified class period, highlighting potential issues with the company's financial performance and stock price volatility [1][2]. Group 1: Lawsuit Details - The lawsuit targets investors who purchased BellRing securities from November 19, 2024, to August 4, 2025, indicating a significant timeframe for potential claims [1]. - Investors have until March 23, 2026, to seek appointment as lead plaintiff representatives, emphasizing the urgency for affected parties to act [2]. Group 2: Financial Performance and Stock Price Impact - On May 6, 2025, BellRing's CFO reported that key retailers reduced their inventory levels, which was expected to negatively impact third-quarter growth by a mid-single-digit percentage. This announcement led to a 19% drop in stock price, from $78.43 to $63.55 per share [3]. - Following the release of its 3Q 2025 financial results on August 4, 2025, BellRing narrowed its fiscal year 2025 net sales outlook due to competitive pressures, resulting in a 33% decline in stock price, from $53.64 to $36.18 per share [4].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. on behalf of investors who acquired its securities during the specified Class Period, alleging misrepresentation and failure to disclose critical information regarding the company's drug development process [1][3]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [2]. Allegations - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study for the drug AMT-130 and downplayed the potential need to delay its Biologics License Application (BLA) timeline due to additional studies [3]. Stock Impact - Following the disclosure on November 3, 2025, that the FDA did not accept the Phase I/II data as primary evidence for a BLA submission, uniQure's stock plummeted over 49%, dropping from $67.69 per share on October 31, 2025, to $34.29 per share on November 3, 2025 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. due to allegations of violations of federal securities laws, particularly concerning misleading statements related to the company's Pivotal Study and its implications for the BLA submission timeline [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that uniQure and its executives made false and misleading statements regarding the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA submission for AMT-130 [5]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II AMT-130 studies would support a BLA submission, contradicting previous statements about the path toward accelerated approval [6]. - Following this disclosure, uniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [7]. Group 2: Class Action Details - Investors who purchased uniQure securities between September 24, 2025, and October 31, 2025, are encouraged to discuss their legal rights and consider seeking the role of lead plaintiff in the class action [3][8]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi encourages anyone with information regarding uniQure's conduct to come forward, including whistleblowers and former employees [9].

Enphase Investors With Significant Losses Are Encouraged To Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson To Discuss Their Legal Rights If you purchased or acquired securities in Enphase between April 22, 2025 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BlackRock TCP Capital Corp due to significant financial losses and alleged violations of federal securities laws [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses from BlackRock TCP between November 6, 2024, and January 23, 2026, to discuss their legal rights [1][4]. - A federal securities class action has been filed against BlackRock TCP, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [4][10]. Group 2: Allegations Against BlackRock TCP - The complaint alleges that BlackRock TCP and its executives made false or misleading statements regarding the valuation of investments and the effectiveness of portfolio restructuring efforts [6]. - Specific allegations include that the company's unrealized losses were understated, leading to an overstatement of the company's net asset value (NAV) [6]. Group 3: Financial Performance and Stock Impact - On February 27, 2025, BlackRock TCP reported a significant weakening of its portfolio, with non-accrual status companies more than doubling and debt investments on non-accrual status increasing by 289% [7]. - The company's NAV fell by 22.44% year over year to $9.23 per share, with total losses reaching $194.9 million, a 186% increase from the previous year [7]. - Following the financial disclosures, the stock price dropped by 9.64% to close at $8.44 per share on February 27, 2025 [7]. - On January 23, 2026, BlackRock TCP disclosed that its NAV per share was actually between $7.05 and $7.09, representing a 19% decrease from the previous quarter and a 23.4% decrease from the prior year [8]. - The stock price fell by 12.97% to close at $5.10 per share on January 26, 2026, following this announcement [9].

Kyndryl Investors With Significant Losses Are Encouraged To Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson To Discuss Their Legal Rights If you purchased or acquired securities in Kyndryl between August 7, 2024 and February 9, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Faruqi & ...

Vistagen Investors With Significant Losses Are Encouraged To Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson To Discuss Their Legal Rights If you purchased or acquired securities in Vistagen between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK, March 4, 2026 /PRNewswire/ -- Faruqi & Fa ...

Core Viewpoint - Endeavor Group Holdings, Inc. is facing a federal securities class action lawsuit due to allegations of making false or misleading statements and failing to disclose critical information regarding the company's financial status and executive earnings [1][1][1] Summary by Relevant Sections Legal Action - Faruqi & Faruqi, LLP is investigating potential claims against Endeavor Group Holdings and has set a lead plaintiff deadline of March 18, 2026 [1][1][1] - The lawsuit claims that Endeavor and its executives violated federal securities laws by misleading investors about the true value of the company's shares and failing to disclose executive earnings related to a merger [1][1][1] Investor Information - Investors who sold Endeavor Class A common stock between January 15, 2025, and March 24, 2025, are encouraged to contact the law firm to discuss their legal rights [1][1][1] - The lead plaintiff will be the investor with the largest financial interest in the case, who will oversee the litigation on behalf of the class [1][1][1] Company Background - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [1][1][1] - The firm is actively seeking information from whistleblowers, former employees, and shareholders regarding Endeavor's conduct [1][1][1]

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Lakeland Industries, Inc. (LAKE) Shareholders To Inquire About Securities Fraud Class Action. ...